The moderate to severe atopic dermatitis (AD) market is at the beginning of a revolution with the recent approval of Sanofi/Regeneron’s first-in-class biologic, Dupixent, and a promising suite of late-phase agents advancing in the pipeline (e.g., Eli Lilly’s baricitinib, Pfizer’s abrocitinib, LEO Pharma’s tralokinumab and delgocitinib, AbbVie’s upadacitinib, Dermira’s lebrikizumab, Galderma’s nemolizumab). In this report, we assess the commercial opportunity remaining in the topical-refractory moderate to severe AD space through a comprehensive analysis of dermatologists’ treatment goals; the key efficacy, safety, and delivery attributes driving prescribing choice; the gaps in treatment left by current therapies; and the interplay of clinical and nonclinical attributes in determining the commercial potential of new AD products.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 30 European dermatologists treating pediatric patients
Key companies:Sanofi, Regeneron, Pfizer, AbbVie, LEO Pharma, Eli Lilly, Incyte
Key drugs: Dupixent, cyclosporine, methotrexate, azathioprine, mycophenolate, oral prednisone
KEY METRICS INCLUDED
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulato